Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians
CA: A Cancer Journal for Clinicians · 2025-12 · 75 (6) · 498-527
DOI: 10.3322/caac.70018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 20.05.2025. Verfasst von Dimitrios Moris und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients with advanced disease to ultimately undergo partial hepatectomy or transplantation with curative intent. This review focuses on all modalities of therapy for HCC, guided by modern‐day practice‐changing randomized data where available. The surgical management of HCC, including resection and transplantation, both of which have evolving criteria for what is considered biologically resectable and transplantable, as well as locoregional therapy (i.e., therapeutic embolization, ablation, radiation, and hepatic arterial infusion), are discussed. Historical and modern‐day practice‐changing trials evaluating immunotherapy with targeted therapies for advanced disease, as well as adjuvant systemic therapy, are also summarized. In addition, this article examines the critical dimension of toxicities and patient‐oriented considerations to ensure a comprehensive and balanced discourse on treatment implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
- Division of Abdominal Transplantation, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
- Patient Advocate Steering Committee, National Cancer Institute Hepatobiliary Task Force, Los Gatos, California, USA.
- Blue Faery, Simi Valley, California, USA.
- Cancer CAREpoint, Los Gatos, California, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
ORCID-Profile: Dimitrios Moris, Alessandro Martinino, Andrew Barbas, Debra Sudan, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A Morse, Michael E Lidsky
Zitieren
APA
Moris, D., Martinino, A., Schiltz, S., Allen, P. J., Barbas, A., Sudan, D., King, L., Berg, C., Kim, C., Bashir, M., Palta, M., Morse, M. A., & Lidsky, M. E. (2025). Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA: A Cancer Journal for Clinicians, 75(6), 498-527. https://doi.org/10.3322/caac.70018
Vancouver
Moris D, Martinino A, Schiltz S, Allen PJ, Barbas A, Sudan D, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA: A Cancer Journal for Clinicians. 2025;75(6):498-527. doi:10.3322/caac.70018
BibTeX
@article{Moris2025,
author = {Moris, Dimitrios and Martinino, Alessandro and Schiltz, Sarah and Allen, Peter J and Barbas, Andrew and Sudan, Debra and King, Lindsay and Berg, Carl and Kim, Charles and Bashir, Mustafa and Palta, Manisha and Morse, Michael A and Lidsky, Michael E},
title = {Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians},
journal = {CA: A Cancer Journal for Clinicians},
year = {2025},
volume = {75},
number = {6},
pages = {498--527},
doi = {10.3322/caac.70018}
}
EUVIMED